One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Issue Highlights
doi : 10.1016/S0360-3016(20)34611-3
OTHER CONTENTS| VOLUME 109, ISSUE 2, PA13-A14, FEBRUARY 01, 2021
Randomized Trials for Esophageal, Liver, Pancreas, and Rectal Cancers
Christopher L. Hallemeier,Florence Huguet,Diana Tait,Jordan Kharofa,Jeffrey R. Olsen,Salma K. Jabbour
doi : 10.1016/j.ijrobp.2020.09.033
ONCOLOGY SCAN| VOLUME 109, ISSUE 2, P305-311, FEBRUARY 01, 2021
Spinal Cord Reirradiation:Balancing Benefit Against Risks
Michael Pinkawa
doi : 10.1016/j.ijrobp.2019.05.067
GRAY ZONE| VOLUME 109, ISSUE 2, P312-313, FEBRUARY 01, 2021
Radiate Once More
Carsten Nieder,Anca-Ligia Grosu
doi : 10.1016/j.ijrobp.2019.05.068
GRAY ZONE| VOLUME 109, ISSUE 2, P314-315, FEBRUARY 01, 2021
Cautious SBRT
Berardino De Bari
doi : 10.1016/j.ijrobp.2019.07.018
GRAY ZONE| VOLUME 109, ISSUE 2, P315, FEBRUARY 01, 2021
Postoperative Stereotactic Body Radiation Therapy, Then Observe
Emma M. Dunne,Mitchell Liu
doi : 10.1016/j.ijrobp.2019.09.020
GRAY ZONE| VOLUME 109, ISSUE 2, P316, FEBRUARY 01, 2021
Evaluation of a 3-Dimensional-Printed Head Simulation Technique for Teaching Flexible Nasopharyngoscopy to Radiation Oncology Residents
Christopher D. Goodman,Justin D. Pautler,Christopher S. Balestrini,Andrew Warner,Donna H. Murrell,David A. Palma
doi : 10.1016/j.ijrobp.2020.08.063
EDUCATION AND TRAINING| VOLUME 109, ISSUE 2, P317-323, FEBRUARY 01, 2021
Radiation Oncology Resident Quality by National Resident Matching Program Metrics From 2007 to 2018
Mudit Chowdhary,Simul D. Parikh,Anna Lee,Rahul D. Tendulkar,Trevor J. Royce
doi : 10.1016/j.ijrobp.2020.08.062
EDUCATION AND TRAINING| VOLUME 109, ISSUE 2, P324-328, FEBRUARY 01, 2021
I Need a Sign: The Growing Need for a Signaling Mechanism to Improve the Residency Match
Wesley J. Talcott,Suzanne B. Evans
doi : 10.1016/j.ijrobp.2020.09.008
EDUCATION AND TRAINING| VOLUME 109, ISSUE 2, P329-331, FEBRUARY 01, 2021
Revising a Research Paper
Theodore S. Lawrence
doi : 10.1016/j.ijrobp.2020.09.035
EDUCATION AND TRAINING| VOLUME 109, ISSUE 2, P332-334, FEBRUARY 01, 2021
US Radiation Oncologists (Re)Defined: An American Society for Radiation Oncology Scope of Practice Study
Claire Y. Fung,Neha Vapiwala,Malcolm D. Mattes,Anna Arnone,Trevor J. Royce,Ronald D. Ennis
doi : 10.1016/j.ijrobp.2020.09.029
THE PROFESSION| VOLUME 109, ISSUE 2, P335-343, FEBRUARY 01, 2021
Travel Time to Radiation Oncology Facilities in the United States and the Influence of Certificate of Need Policies
Joshua N. Herb,Rachael T. Wolff,Philip M. McDaniel,G. Mark Holmes,Trevor J. Royce,Karyn B. Stitzenberg
doi : 10.1016/j.ijrobp.2020.08.059
THE PROFESSION| VOLUME 109, ISSUE 2, P344-351, FEBRUARY 01, 2021
Use of Multi-Site Radiation Therapy for Systemic Disease Control
Roshal R. Patel,Vivek Verma,Hampartsoum B. Barsoumian,Nahum Puebla-Osorio,Maria Angelica Cortez,James W. Welsh
doi : 10.1016/j.ijrobp.2020.08.025
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P352-364, FEBRUARY 01, 2021
Do Coordinated Knowledge Translation Campaigns Persuade Radiation Oncologists to Use Single-Fraction Radiation Therapy Compared With Multiple-Fraction Radiation Therapy for Bone Metastases?
Shaheer Shahhat,Nikesh Hanumanthappa,Youn Tae Chung,Aldrich Ong,Kim Tran,Julian O. Kim
doi : 10.1016/j.ijrobp.2020.08.056
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P365-373, FEBRUARY 01, 2021
Behavioral Determinants of Canadian Radiation Oncologists’ Use of Single Fraction Palliative Radiation Therapy for Uncomplicated Bone Metastases
Janet E. Squires,Sarah Asad,Melissa Demery Varin,Ian D. Graham,Jeremy M. Grimshaw,Kristopher Dennis
doi : 10.1016/j.ijrobp.2020.09.030
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P374-386, FEBRUARY 01, 2021
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
Matthew P. Deek,Kekoa Taparra,Dyda Dao,Sean S. Park,Bradley J. Stish,Phuoc T. Tran
doi : 10.1016/j.ijrobp.2020.08.030
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P387-395, FEBRUARY 01, 2021
Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation
Brandon A. Dyer,Christine H. Feng,Ramez Eskander,Loren K. Mell,Michael McHale,Jyoti S. Mayadev
doi : 10.1016/j.ijrobp.2020.09.016
CLINICAL INVESTIGATION|CME| VOLUME 109, ISSUE 2, P396-412, FEBRUARY 01, 2021
Novel therapies combined with radiation continue to be of significant interest in the developmental treatment paradigm of gynecologic cancers. Clinical implementation of immunotherapy in oncology has rapidly changed the treatment landscape, options, paradigm, and outcomes through clinical trials. Immunotherapy has emerged as a therapeutic pillar in the treatment of solid tumors with demonstrable synergistic activity when combined with radiation therapy and chemoradiotherapy by an alteration or enhancement of the immune system. In solid tumors, radiation therapy induces migration of dendritic cells, T cell activation, and proliferation, and increases in tumor-infiltrating lymphocytes. These immunomodulatory effects in conjunction with immune checkpoint blockade are currently under active investigation in the adjuvant, definitive, and metastatic settings. Results from early phase trials demonstrate promising efficacy and overall tolerable toxicity profiles of combined modality treatment. There is significant interest in optimizing the treatment for patients with locally advanced cervical cancer beyond the standard of care—chemoradiation—which has been in place for the last 30 years. The majority of cervical cancer emerges after persistent infection with a high-risk subtype of the human papillomavirus, where viral oncoproteins lead to cellular changes and immortalization. As a result, immune tolerance can develop, resulting in cancer. Knowledge of the mechanism of human papillomavirus–related oncogenesis suggests that immune therapy or checkpoint blockade can reinvigorate an antitumor immune response. Current clinical trials are exploring the therapeutic potential of these approaches. Uterine cancers have been grouped into 4 molecular subclasses by their driver mutations, mutational burden, and copy-number alterations. Of these subgroups, the polymerase epsilon–mutated and microsatellite-unstable may represent up to 40% of endometrial cancers, and they have been shown to be immunogenic. Because of the inherent immunogenicity of these MSI-high tumors, combined immune modulation strategies, including chemotherapy, radiation, and immunotherapy and immune checkpoint inhibitor therapy, are being explored to improve treatment outcomes. In this review, we explore current immunomodulatory and multimodality therapeutic approaches in the treatment of cervical and uterine cancer through ongoing clinical trials investigating the combination of immunotherapy and radiation therapy.
NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update
William Small Jr.,Walter R. Bosch,Mathew M. Harkenrider,Catheryn M. Yashar,Kathryn A. Winter,David K. Gaffney
doi : 10.1016/j.ijrobp.2020.08.061
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P413-424, FEBRUARY 01, 2021
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Bradford A. Perez,Sungjune Kim,Minhsuan Wang,Michael J. Schell,Jose R. Conejo-Garcia,Scott J. Antonia
doi : 10.1016/j.ijrobp.2020.09.031
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P425-435, FEBRUARY 01, 2021
Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
Pierre Loap,Delphine Loirat,Frederique Berger,Alain Fourquet,Monia Ezzalfani,Youlia Kirova
doi : 10.1016/j.ijrobp.2020.09.032
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P436-440, FEBRUARY 01, 2021
Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial
Dario Pasalic,Eric A. Strom,Pamela K. Allen,George H. Perkins,Welela Tereffe,Karen E. Hoffman
doi : 10.1016/j.ijrobp.2020.09.009
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P441-448, FEBRUARY 01, 2021
Trends in Use of Hypofractionated Whole Breast Radiation in Breast Cancer: An Analysis of the National Cancer Database
Steven G. Woodward,Karan Varshney,Pramilla R. Anne,Brandon J. George,Alliric I. Willis
doi : 10.1016/j.ijrobp.2020.09.004
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P449-457, FEBRUARY 01, 2021
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer
Jacob S. Witt,Aleksandra Kuczmarska-Haas,Meghan Lubner,Mark A. Ritter,Pranshu Mohindra,Michael F. Bassetti
doi : 10.1016/j.ijrobp.2020.09.010
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P458-463, FEBRUARY 01, 2021
Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study
Nalee Kim,Jason Cheng,Wen-Yen Huang,Victor H.F. Lee,Chul Seung Kay,Jinsil Seong
doi : 10.1016/j.ijrobp.2020.09.038
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P464-473, FEBRUARY 01, 2021
Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy
Cheng-Hsiang Lo,Hsin-Lun Lee,Chih-Weim Hsiang,Chun-You Chen,Jason Chia-Hsien Cheng,Wen-Yen Huang
doi : 10.1016/j.ijrobp.2020.09.001
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P474-484, FEBRUARY 01, 2021
Health-Related Quality of Life Outcomes in Head and Neck Cancer: Results From a Prospective, Real-World Data Study With Brazilian Patients Treated With Intensity Modulated Radiation Therapy, Conformal and Conventional Radiation Techniques
Marcos Santos,Lu?s Felipe Oliveira e Silva,Hugo F. Kohler,Doralina Rabello,Christian Domenge,Luiz Paulo Kowalski
doi : 10.1016/j.ijrobp.2020.09.044
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P485-494, FEBRUARY 01, 2021
Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients
Wen-Shan Liu,Kuo-Wang Tsai,Bor-Hwang Kang,Kuo-Ping Chang,Hsiu-Min Chen,Yaoh-Shiang Lin
doi : 10.1016/j.ijrobp.2020.09.034
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P495-504, FEBRUARY 01, 2021
Improving the Pediatric Patient Experience During Radiation Therapy-A Children’s Oncology Group Study
Douglas E. Holt,Susan M. Hiniker,John A. Kalapurakal,Alyssa Wojcik,Cheng-Chia Wu,Sarah A. Milgrom
doi : 10.1016/j.ijrobp.2020.09.002
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P505-514, FEBRUARY 01, 2021
Diffusion Tensor Imaging-Based Analysis of Baseline Neurocognitive Function and Posttreatment White Matter Changes in Pediatric Patients With Craniopharyngioma Treated With Surgery and Proton Therapy
Jinsoo Uh,Thomas E. Merchant,Heather M. Conklin,Abbas Babajani-Feremi,Daniel J. Indelicato,Chia-ho Hua
doi : 10.1016/j.ijrobp.2020.08.060
CLINICAL INVESTIGATION| VOLUME 109, ISSUE 2, P515-526, FEBRUARY 01, 2021
Positron Emission Tomography Imaging of Functional Transforming Growth Factor ? (TGF?) Activity and Benefit of TGF? Inhibition in Irradiated Intracranial Tumors
Alba Gonzalez-Junca,Oliver Reiners,Luis D. Borrero-Garcia,Henry VanBrocklin,Benjamin L. Franc,Mary Helen Barcellos-Hoff
doi : 10.1016/j.ijrobp.2020.09.043
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P527-539, FEBRUARY 01, 2021
A Novel Anticancer Therapeutic Strategy to Target Autophagy Accelerates Radiation-Associated Atherosclerosis
Ruosen Yuan,Zhe Sun,Jiali Cai,Xiaolong Fu,Linghong Shen,Ben He
doi : 10.1016/j.ijrobp.2020.09.007
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P540-552, FEBRUARY 01, 2021
Pharmacologic Inhibition of HIF-1? Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy
Jae-Kyung Nam,A-Ram Kim,Seo-Hyun Choi,Jaeho Cho,Hae-June Lee,Yoon-Jin Lee
doi : 10.1016/j.ijrobp.2020.09.006
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P553-566, FEBRUARY 01, 2021
Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells
Konstanze Lettau,Daniel Zips,Mahmoud Toulany
doi : 10.1016/j.ijrobp.2020.09.005
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P567-580, FEBRUARY 01, 2021
Dietary Methionine Supplementation Exacerbates Gastrointestinal Toxicity in a Mouse Model of Abdominal Irradiation
Laura E. Ewing,Charles M. Skinner,Rupak Pathak,Marjan Boerma,Martin Hauer-Jensen,Igor Koturbash
doi : 10.1016/j.ijrobp.2020.09.042
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P581-593, FEBRUARY 01, 2021
Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors
Alexander Helm,Walter Tinganelli,Palma Simoniello,Claudia Fournier,Takashi Shimokawa,Marco Durante
doi : 10.1016/j.ijrobp.2020.09.041
BIOLOGY CONTRIBUTION| VOLUME 109, ISSUE 2, P594-602, FEBRUARY 01, 2021
High-Resolution pO2 Imaging Improves Quantification of the Hypoxic Fraction in Tumors During Radiation Therapy
Xu Cao,Srinivasa Rao Allu,Shudong Jiang,Harold M. Swartz, MD, MSPH, PhD,Sergei A. Vinogradov, PhD,Brian W. Pogue, PhD
doi : 10.1016/j.ijrobp.2020.09.046
PHYSICS CONTRIBUTION| VOLUME 109, ISSUE 2, P603-613, FEBRUARY 01, 2021
Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study
Jeremiah W. Sanders,Aradhana M. Venkatesan,Chad A. Levitt,Carl P. Weaver,Jingfei Ma,Steven J. Frank
doi : 10.1016/j.ijrobp.2020.09.040
PHYSICS CONTRIBUTION| VOLUME 109, ISSUE 2, P614-625, FEBRUARY 01, 2021
Establishment of Microbeam Radiation Therapy at a Small-Animal Irradiator
Franziska Treibel,Mai Nguyen,Mabroor Ahmed,Stephanie E. Combs,Thomas E. Schmid,Stefan Bartzsch
doi : 10.1016/j.ijrobp.2020.09.039
PHYSICS CONTRIBUTION| VOLUME 109, ISSUE 2, P626-636, FEBRUARY 01, 2021
Recruitment Challenges and Opportunities for Radiation Oncology Residency Programs During the 2020-2021 Virtual Residency Match
Bismarck Odei,Emma Brey Holliday,Reshma Jagsi,Allen M. Chen,Raju Raval,Denise Fabian
doi : 10.1016/j.ijrobp.2020.08.024
BRIEF OPINION| VOLUME 109, ISSUE 2, P637-638, FEBRUARY 01, 2021
In Regard to Odei et al.
Jenna M. Kahn,Navjot Sandhu,Erqi L. Pollom
doi : 10.1016/j.ijrobp.2020.08.067
COMMENTS| VOLUME 109, ISSUE 2, P639-640, FEBRUARY 01, 2021
In Regard to Bovi et al.
José A. Pe?agar?cano
doi : 10.1016/j.ijrobp.2020.08.065
COMMENTS| VOLUME 109, ISSUE 2, P640-641, FEBRUARY 01, 2021
In Reply to Pe?agar?cano
Joseph A. Bovi,Christopher J. Schultz
doi : 10.1016/j.ijrobp.2020.08.066
COMMENTS| VOLUME 109, ISSUE 2, P641, FEBRUARY 01, 2021
In Regard to Datta et al.
Sergey Roussakow
doi : 10.1016/j.ijrobp.2020.09.011
COMMENTS| VOLUME 109, ISSUE 2, P641-642, FEBRUARY 01, 2021
In Reply to Roussakow
Niloy R. Datta,Emanuel Stutz,Silvia Gomez,Stephan Bodis
doi : 10.1016/j.ijrobp.2020.09.012
COMMENTS| VOLUME 109, ISSUE 2, P642-644, FEBRUARY 01, 2021
Meetings
doi : 10.1016/S0360-3016(20)34634-4
ANNOUNCEMENT| VOLUME 109, ISSUE 2, P645, FEBRUARY 01, 2021
